What an incredible day! 🎓
Graduated from @UniofOxford with this fabulous bunch : Inaugural cohort of the @Oxford_NDPH MSc in Clinical Trials! We made it, guys! 🙌
Today, three of the authors have retracted "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis" Read the Retraction notice and statement from The Lancet https://t.co/pPNCJ3nO8n
The @US_FDA authorised remdesivir for COVID-19 on the basis of 1 outcome from the NIAID trial. This outcome was switched, the trial is unpublished, and we have no good evidence remdesivir reduces mortality. Our piece for @CebmOxford@NDevito1@JKAronson https://t.co/48vXkI00ju
DAPA HF: 4744 pts w/HFrEF w/or w/o diabetes rand to SGLT2i dapaglifozin vs placebo. Med 18 mo FU. CV death, HF hosp or urgent HF visit reduced by 26%, p<0.0001. Sign decrease in CV death as well as HF events. All death decr. Benefits identical in pts w/& w/o DM. New Rx for HFrEF!
The HUAWEI Heart study found continuous home monitoring w/ mobile health devices equipped w/ PPG technology could be a feasible approach for screening & early detection of #AFib in large populations. #ESCCongress#JACC https://t.co/IIVegp1oqc
DAPA-HF trial at #ESCCongress: significant reduction of events in HFrEF patients by dapagliflozine. Half of the 5744 pts had diabetes, the others did not: same effect in both groups.
SGLT2 inhibitors just better diuretics or the "statins of HF"?
@escardio#cardiotwitter